# ClinicalTrials.gov record NCT04042142

> PeptideScanner retained ClinicalTrials.gov record NCT04042142 at 2026-07-30T19:32:59.855Z. Its registry update date was 2022-11-04, and PeptideScanner's reviewed identity mapping was glucagon.

- Evidence object: `story:clinicaltrials-gov-nct04042142-glucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-11-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04042142-glucagon/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04042142-glucagon-v1.json
- Content SHA-256: `3fbad0046c03eddce5c2d1e85a4773284db1675e9e17926ea4c731a765c115f1`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT04042142 ([`ctg-observation-nct04042142-2022-11-04-3a850dc06299`](#source-ctg-observation-nct04042142-2022-11-04-3a850dc06299))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04042142 at 2026-07-30T19:32:59.855Z. Its registry update date was 2022-11-04, and PeptideScanner's reviewed identity mapping was glucagon. ([`ctg-observation-nct04042142-2022-11-04-3a850dc06299`](#source-ctg-observation-nct04042142-2022-11-04-3a850dc06299))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04042142 at 2026-07-30T19:32:59.855Z. Its registry update date was 2022-11-04, and PeptideScanner's reviewed identity mapping was glucagon. ([`ctg-observation-nct04042142-2022-11-04-3a850dc06299`](#source-ctg-observation-nct04042142-2022-11-04-3a850dc06299))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04042142-2022-11-04-3a850dc06299`](#source-ctg-observation-nct04042142-2022-11-04-3a850dc06299))

## Sources

<a id="source-ctg-observation-nct04042142-2022-11-04-3a850dc06299"></a>
- **ClinicalTrials.gov record NCT04042142 · retained source version 2022-11-04:3a850dc0629992e1f0e673f5b5b04ea067f6d8e9a7a56b78bd890ca8ed6b56d4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04042142) (`ctg-observation-nct04042142-2022-11-04-3a850dc06299`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04042142." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04042142-glucagon-v1.json SHA-256: 3fbad0046c03eddce5c2d1e85a4773284db1675e9e17926ea4c731a765c115f1.